Significantly lower risk is seen for viral clearance. 3 studies from 2 independent teams (all from the same country) show significant benefit.
Meta analysis using the most serious outcome reported shows 26% [-14‑52%] lower risk, without reaching statistical significance. Results are worse for peer-reviewed studies. Currently all studies are RCTs.
Currently there is limited data, with only 1 control event for the most serious outcome in trials to date. Studies to date are from only 2 different groups.
Variants may be resistant to ensitrelvir1.
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. All data and sources to reproduce this analysis are in the appendix.
Covid Analysis et al., Jan 2025, preprint, 1 author.
